Disc Medicine Updates Clinical Programs for DISC-3405 and Bitopertin

Disc Medicine is advancing its two primary clinical candidates, DISC-3405 and bitopertin, as the company adjusts its regulatory strategy following FDA feedback. The firm is focused on demonstrating clinical efficacy for polycythemia vera while pursuing a traditional approval pathway for its erythropoietic protoporphyria (EPP) treatment.

Clinical Progress for DISC-3405

The company’s Phase II study of DISC-3405 for polycythemia vera has yielded positive results, according to recent company commentary. Data from the trial shows an 85% reduction in phlebotomy rates among participants, and 78% of patients on stable doses achieved a phlebotomy-free status.

"The most kind of side effect-free control of hematocrit that you can achieve for these patients," said John Quisel, CEO of Disc Medicine, in a statement at the Wells Fargo healthcare conference.

Regulatory Pivot for Bitopertin

Disc Medicine is adjusting its development plan for bitopertin, a treatment for EPP. After receiving a Complete Response Letter from the FDA regarding an earlier bid for accelerated approval, the company is shifting toward a traditional regulatory path. Quisel characterized the initial attempt at accelerated approval as "a highly controversial path" for the program.

Financial Position and Market Valuation

As a clinical-stage biotechnology firm, Disc Medicine remains pre-revenue. According to recent financial disclosures, the company reported a negative EBITDA of $268 million over the last twelve months. As of September 11, 2026, Disc Medicine (NASDAQ: IRON) trades at $70.06 per share, resulting in a market capitalization of approximately $2.94 billion.

What Is at Stake for Disc Medicine

The company's ability to navigate the transition from early-stage trials to late-stage regulatory submission drives its current valuation. By moving away from the accelerated approval route for bitopertin, Disc Medicine aims to align its clinical data with the requirements of a traditional FDA review process. The success of these two programs is necessary for the firm, as it currently lacks commercialized products to offset its ongoing operational burn rate.